Educational Reference Only Not medical advice. No sourcing, vendor, pricing, or compounding information provided. Consult a qualified healthcare provider.

Peptide Desk ReferencePDR
Metabolic/GLP-1FDA-approvedEvidence: A

Exenatide

Also known as: Byetta, Bydureon, Bydureon BCise, AC2993, Synthetic Exendin-4

GLP-1 Receptor AgonistType 2 Diabetes

Overview

Clinical Summary

Exenatide is the first-in-class GLP-1 receptor agonist, originally derived from the saliva of the Gila monster lizard (Heloderma suspectum). The active compound exendin-4 shares 53% sequence homology with human GLP-1 and is naturally resistant to DPP-4 degradation. Two formulations are approved for T2D: immediate-release exenatide (Byetta, 5 and 10 mcg twice daily) and extended-release exenatide (Bydureon/Bydureon BCise, 2 mg once weekly). While exenatide was the foundational GLP-1RA that validated the class, it has been largely overtaken by newer agents with superior efficacy, more convenient dosing, and proven cardiovascular benefits. It does not carry an obesity indication.

Plain Language Summary

Exenatide was the first medication in the GLP-1 class, approved for type 2 diabetes. It is a synthetic version of a protein originally found in the saliva of the Gila monster lizard, which happens to work like the human GLP-1 hormone. It comes in two forms: Byetta, which is injected twice daily before meals, and Bydureon, a once-weekly injection. While it was a groundbreaking medication when introduced, newer options like semaglutide and tirzepatide offer greater blood sugar control and weight loss. Exenatide is not specifically approved for weight loss, though it does cause modest weight reduction.

Mechanism of Action

Exenatide (synthetic exendin-4) is a full agonist at the GLP-1 receptor. Unlike native GLP-1, which has a half-life of approximately 2 minutes due to rapid DPP-4 cleavage, exendin-4 has a substitution at position 2 (glycine replacing alanine) that confers resistance to DPP-4 degradation, extending the immediate-release half-life to 2.4 hours. The extended-release formulation uses poly(D,L-lactide-co-glycolide) microspheres to create a subcutaneous depot that releases exenatide gradually over weeks. Pharmacological actions include glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite reduction. Exenatide does not have an albumin-binding moiety, distinguishing its pharmacokinetic profile from acylated GLP-1 analogues.

Evidence Summary

Evidence Grade:Evidence: A

The initial Phase 3 program (AMIGO trials) established Byetta for T2D, showing HbA1c reductions of 0.8 to 1.0% and progressive weight loss of 1.6 to 2.8 kg at 30 weeks. The DURATION program compared once-weekly to twice-daily exenatide: DURATION-1 showed greater HbA1c reduction with weekly dosing (1.9% vs 1.5%) with less nausea. EXSCEL (n=14,752, median 3.2 years) was the cardiovascular outcomes trial, which met noninferiority for MACE (HR 0.91, 95% CI 0.83-1.00) but did not achieve superiority (p=0.06). Limitations include modest efficacy compared to later-generation GLP-1RAs, failure to demonstrate cardiovascular superiority, and high discontinuation rates in the EXSCEL trial (43%).

Safety Profile

The safety profile is well-characterized over nearly two decades of clinical use. Nausea is the most common adverse event (approximately 44% with twice-daily, less with weekly formulation) and is typically transient. Bydureon-specific adverse events include injection site nodules (subcutaneous microspheres) in approximately 10% of patients. Post-marketing reports of acute pancreatitis led to labeling updates, though a causal relationship has not been definitively established. The FDA added a boxed warning for thyroid C-cell tumors to the Bydureon label. Acute kidney injury has been reported, primarily in patients with pre-existing renal impairment experiencing severe GI events. Immunogenicity: anti-exenatide antibodies develop in approximately 45% of patients on Byetta and 60% on Bydureon, though high-titer antibodies affecting efficacy are uncommon.

Contraindications

  • Personal or family history of medullary thyroid carcinoma (Bydureon only)
  • Multiple endocrine neoplasia type 2 (Bydureon only)
  • Known hypersensitivity to exenatide or any excipients
  • Severe gastrointestinal disease including gastroparesis
  • End-stage renal disease or severe renal impairment (CrCl less than 30 mL/min)

Adverse Events

  • Nausea (most common, higher with twice-daily formulation)
  • Vomiting
  • Diarrhea
  • Injection site nodules (extended-release formulation)
  • Headache
  • Dizziness
  • Anti-exenatide antibody formation

Interactions

  • Delays gastric emptying; take oral medications at least 1 hour before exenatide injection when possible
  • Increased risk of hypoglycemia with sulfonylureas; consider reducing sulfonylurea dose
  • Caution with warfarin: case reports of increased INR; monitor when initiating or adjusting exenatide
  • Should not be used with other GLP-1RA products or with insulin (Byetta only; Bydureon is not studied with prandial insulin)

Regulatory Notes

Byetta (exenatide 5 and 10 mcg injection) was FDA-approved in April 2005, making it the first GLP-1RA on the market. Bydureon (exenatide extended-release 2 mg) was approved in January 2012. Bydureon BCise (autoinjector formulation) was approved in October 2017. All were originally developed by Amylin Pharmaceuticals and are now marketed by AstraZeneca. Market share has declined substantially with the availability of newer GLP-1RAs.

Monitoring Considerations

Monitor HbA1c and fasting glucose regularly. Assess renal function before initiation and periodically during treatment; use is not recommended in severe renal impairment. Monitor for signs and symptoms of pancreatitis (persistent severe abdominal pain). For Bydureon, inspect injection sites for nodules. Monitor for anti-drug antibody effects if glycemic response is suboptimal. Assess GI tolerability, particularly during the initial weeks of Byetta therapy.

These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.

Stability and Handling Notes

Byetta: store refrigerated at 2 to 8 degrees C. After first use, keep at room temperature (up to 25 degrees C) and use within 30 days. Protect from light. Bydureon BCise: store refrigerated. May be kept at room temperature (up to 30 degrees C) for up to 4 weeks. Each autoinjector is for single use. The extended-release suspension requires adequate mixing by tapping before injection. Do not freeze either formulation.

References

  1. 1
    RCT

    Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients with Type 2 Diabetes

    DeFronzo RA, Ratner RE, Han J, et al. (2005). Diabetes Care

    Key findings: Phase 3 trial of exenatide 5 and 10 mcg BID in T2D patients on metformin. HbA1c reductions of 0.4% (5 mcg) and 0.8% (10 mcg) vs placebo. Progressive weight loss of approximately 1.6 kg at 30 weeks.

    Limitations: 30-week duration. Modest HbA1c reductions compared to later GLP-1RAs.

    View source
  2. 2
    RCT

    Exenatide Once Weekly versus Twice Daily for the Treatment of Type 2 Diabetes (DURATION-1)

    Drucker DJ, Buse JB, Taylor K, et al. (2008). Lancet

    Key findings: Extended-release exenatide 2 mg weekly produced greater HbA1c reduction (1.9% vs 1.5%) and less nausea than immediate-release exenatide 10 mcg BID at 30 weeks. Similar weight loss between formulations.

    Limitations: Open-label. No placebo arm. Injection site nodules more common with weekly formulation.

    View source
  3. 3
    FDA label

    BYETTA (exenatide) injection Prescribing Information

    AstraZeneca Pharmaceuticals LP. (2022). FDA

    Key findings: Full prescribing information including boxed warning for thyroid C-cell tumors (Bydureon), indication for T2D, dosing, contraindications including history of pancreatitis, and postmarketing reports.

    Limitations: Label information; not primary research.

    View source
  4. 4
    RCT

    Exenatide Extended-Release and Cardiovascular Outcomes (EXSCEL)

    Holman RR, Bethel MA, Mentz RJ, et al. (2017). New England Journal of Medicine

    Key findings: Cardiovascular outcomes trial in 14,752 T2D patients. Exenatide weekly did not achieve superiority for MACE reduction (HR 0.91, 95% CI 0.83-1.00, p=0.06) but met noninferiority. Reduction in all-cause mortality was observed as a secondary endpoint.

    Limitations: Did not meet superiority for primary endpoint. High discontinuation rate (43% in exenatide group).

    View source

Last reviewed: 2026-03-24 | Version: 1 | Status: Published

Want to discuss this compound with a qualified physician?

The Peptide Association has verified over 160 licensed providers specializing in peptide therapy, with telehealth options available in most states.

Find a Verified Provider